RESUMEN

PALABRAS CLAVE

REFERENCIAS

1. Peacock AJ. Prevention and early diagnosis of pulmonary hypertension. Eur Respir Mon 2003;27:227-242.

2. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107:216-223.

3. Benza RL, Gomberg-Maitland M, Miller DP, et al. The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest 2012;141:354-362.

4. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-1030.

5. Brown LM, Chen H, Halpern S, et al. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest 2011;140:19-26.

6. Manual SEPAR de Procedimientos. Técnicas y Procedimientos en hipertensión pulmonar. Comité Científico de SEPAR. Barberà JA, Bueno N, Chamarro E, et al. Publicaciones Permanyer; 2004.

8. American Thoracic Society; American College of Chest Physicians. ATS/ACCP Statement on Cardiopulmonary Exercise Testing. Am J Respir Crit Care Med 2003;167:211-277.

9. Normativa SEPAR. Pruebas de ejercicio cardiopulmonar. Arch Bronconeumol 2001;37:247-268.

10. ATS Committee on Proficiency Standard for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-117.

11. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487-492.

12. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-788.

14. Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998;31:202-208.

15. Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006;129:1313-1321.

16. Galié N, Hoeper M, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-2537.

17. Nagaya N, Uematsu M, Satoh T, et al. Serum uric acid levels correlate with severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 1999;160:487-492.

18. Torbicki A, Kurzyna M, Kuca P, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003;108:844-848.

19. Rhodes C, Wharton J, Howard L, et al. Red cell distribution with outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. Heart 2011;97:1054-1060.

20. Heresi G, Aytekin M, Newman J, et al. Plasma levels of high-density lipoprotein cholesterol and outcomes in pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;182:661-668.

22. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:40S-47S.

23. Rubin LJ; American College of Chest Physicians. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines Executive summary. Chest 2004;126:4S-6S.

24. Humbert M, McLaughlin VV. The 4th World Symposium on Pulmonary Hypertension Introduction. J Am Coll Cardiol 2009;54(Suppl 1):S1-S2.

25. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-2537.

26. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009;119:2250-2294.

27. Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006;48:2546-2552.

28. Rumbak MJ, Cox J, Dray D, et al. The right heart catheterization for the pulmonologist. The diagnosis, management, and prognosis of patients with pulmonary arterial hypertension. Clin Pulm Med 2010;17:239-243.

29. Escribano P, Barberà JA, Suberviola V. Evaluación diagnóstica y pronóstica actual de la hipertensión pulmonar. Rev Esp Cardiol 2010;63:583-596.

30. Gómez MA, Escribano P. Protocolos de actuación en hipertensión arterial pulmonar. España: Edimsa; 2010.p.1-133.

31. Barberà JA, Escribano P, Morales P, et al. Standards of care in pulmonary hypertension. Consensus Statement of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Cardiology (SEC). Arch Bronconeumol 2008;44:87-99.

32. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005;26:858-863.

34. Said SI. Mediators and modulators in pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2006;291:547-558.

35. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-1436.

36. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-277.

37. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000;342:1866-1870.

38. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-804.

39. Barst RJ, McGoon M, McLaughlin VV, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119-2125.

40. Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008;31:407-415.

41. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.

42. Galié N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:529-535.

43. Pepke-Zaba J, McNeill K. Inhaled nitric oxide. In: Peacock AJ, Rubin LJ, editors. Pulmonary circulation, diseases and treatment. 2nd ed. Arnold, London; 2004.p.282-293.

44. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-2157.

45. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894-2903.

46. Galiè N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30:394-403.

47. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009;30:2493-2537.

48. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. J Am Coll Cardiol 2009;53:1573-1619.

49. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-3111.

51. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for Diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-2537.

52. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-1436.

53. Toews ML, Bylund DB. Pharmacologic principles for combination therapy. Proc Am Thorac Soc 2005;2:282-289.

54. Abraham T, Wu G, Vastey F, Rapp J, Saad N, Balmir E. Role of combination therapy in the treatment of pulmonary arterial hypertension. Pharmacotherapy 2010;30:390-404.

55. Bai Y, Sun L, Hu S, Wei Y. Combination therapy in pulmonary arterial hypertension: a meta-analysis. Cardiology 2011;120:157-165.

56. Fox BD, Shimony A, Langleben D. Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension. Am J Cardiol 2011;108:1177-1182.

57. Itoh T, Nagaya N, Fujii T, et al. A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;169:34-38.

58. Kemp K, Savale L, O´Callaghan DS, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J Heart Lung Transplant 2012;31:150-158.

59. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary artery hypertension: BREATHE-2. Eur Respir J 2004:24:353-359.

60. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257-1263.

61. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28:691-694.

62. Simonneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149:521-530.

63. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010;55:1915-1922.

65. D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-349.

66. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156-163.

67. Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 2007;30:1103-1110.

68. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010;122:164-172.

69. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-2537.

70. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005;26:858-863.

71. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24:353-359.

72. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257-1263.

73. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28:691-694.

74. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894-2903.

75. Gruenig E, Michelakis E, Vachiery JL, et al. Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. J Clin Pharmacol 2009;49:1343-1352.

76. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149:521-530.

77. Wilkens H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104:1218-1222.

78. Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003;42:158-164.

80. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based, study. Arch Intern Med 1998;158:585-593.

81. Estudio sobre la enfermedad trombo­embólica venosa en España. Disponible en: http://www.fesemi.org/grupos/e_tromboembolica/publicaciones/estudio_etv.pdf

82. Tapson VF, Humbert M. Incidence and prevalence of chronic thromboembolic pulmonary hypertension: from acute to chronic pulmonary embolism. Proc Am Thorac Soc 2006;3:564-567.

83. Dartevelle P, Fadel E, Mussot S, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2004;23:637-648.

84. Peacock A, Simonneau G, Rubin L. Controversies, uncertainties and future research on the treatment of chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 2006;3:608-614.

86. Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar Grupo de Trabajo de la Sociedad Europea de Cardiología (ESC) y la European Respiratory Society (ERS) para el diagnóstico y tratamiento de la hipertensión pulmonar, en colaboración con la International Society of Heart and Lung Transplantation (ISHLT) Autores/miembros del Grupo de Trabajo: Nazzareno Galiè (coordinador) (Italia)*, Marius M. Hoeper (Alemania), Marc Humbert (Francia), Adam Torbicki (Polonia), Jean-Luc Vachiery (Francia), Joan Albert Barberá (España), Maurice Beghetti (Suiza), Paul Corris (Reino Unido), Sean Gaine (Irlanda), J. Simon Gibbs (Reino Unido), Miguel Ángel Gómez-Sánchez (España), Guillaume Jondeau (Francia), Walter Klepetko (Austria), Christian Opitz (Alemania), Andrew Peacock (Reino Unido), Lewis Rubin (Estados Unidos), Michael Zellweger (Suiza) y Gerald Simonneau (Francia). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J doi:10.1093/eurheartjehp297.

87. Barberà JA, Escribano P, Morales P, et al. Standards of care in pulmonary hypertension. Consensus statement of the Spanish Society of Pulmonology and Thoracic Surgery 8SEPAR) and the Spanish Society of Cardiology (SEC). Rev Esp Cardiol 2008;61:170-184.

88. Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006;48:2546-2552.

89. Dartevelle P, Fadel E, Mussot S, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2004;23:637-648.

90. Bresser P, Fedullo PF, Auger WR, et al. Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J 2004;23:595-600.

91. Reichenberger F, Voswinckel R, Enke B, et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J 2007;30:922-927.

92. Jaïs X, D’Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 2008;52:2127-2134.

94. Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917-1928.

95. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-1030.

96. Naval N. Epidemiología de la hipertensión pulmonar. Insuf Card 2009;5:192-196.

97. Melero MJ. Estado actual de la hipertensión arterial pulmonar. Insuf Card 2009;4:23-26.

98. Simonneau G, Robbins I, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43-54.

99. Gabbay E, Yeow W, Playford D. Pulmonary arterial hypertension (PAH) is an uncommon cause of pulmonary hypertension (PH) in an unselected population: the Armadale echocardiography study. Am J Resp Crit Care Med 2007;175:A713.

100. Machado RD, Eickelberg O, Elliott CG, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S32-S42.

102. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (Gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;67:737-474.

103. Thomsom JR, Machado RD, Pauciulo MW, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-b family. J Med Genet 2000; 37:741-745.

104. Baloira A, Vilariño C, Leiro V, Valverde D. Mutaciones en el gen que codifica BMPR2 en pacientes con hipertensión arterial pulmonar esporádica. Arch Bronconeumol 2008;44:29-34.

105. Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001;108:1141-1150.

106. Trembath RC, Thomsom JR, Machado RD, et al. Clinical and molecular genetics features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001;345:325-334.

107. Grünig E, Jansen B, Mereles D, et al. Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene. Circulation 2000;102:1145-50.

108. Sztrymf B, Coulet F, Girerd B, et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 2008;177:1377-1383.

110. Lopes AA, Bandeira AP, Flores PC, Santana MV. Pulmonary hypertension in Latin America: pulmonary vascular disease: the global perspective. Chest 2010;137(6 Suppl):78S-84S.

111. Naval N. Epidemiología de la hipertensión pulmonar. Insuf Card 2010;5:192-196.

112. Saavedra L, Arteta F, Guzmán S, Vergara G, Olivares D. Revisión contemporánea: hipertensión pulmonar. Avances Cardiol 2009;29:165-178.

113. Comité de Insuficiencia Cardiaca e Hipertensión Arterial Pulmonar. Federación Argentina de Cardiología. Diseño del Registro HINPULSAR. Hipertensión pulmonar y asociaciones en la Argentina. Insuf Card 2010;5:126-131.

114. Zagolin M, Wainstein E, Polentzi G, Parra C. Caracterización clínica funcional y hemodinámica de la población con hipertensión pulmonar arterial evaluada en el Instituto Nacional del Tórax. Rev Med Chile 2006;134:589-595.

115. Enríquez A, Castro P, Sepúlveda P, et al. Cambios en el pronóstico a largo plazo de la hipertensión pulmonar. Rev Med Chile 2011;139:327-333.

116. Sandoval J, Bauerle O, Palomares A, et al. Survival in primary pulmonary hypertension. Validation of prognostic equation. Circulation 1994;89:1733-1744.

117. Lupi-Herrera E, Santos ML, Pulido T, Sandoval J. Interpretación de la relación presión-flujo en la hipertensión pulmonar idiopática. Arch Cardiol Mex 2010;80:163-173.

118. Lupi-Herrera E, Sandoval J, Figueroa J, et al. Left and right ventricular power: outputs are the strongest hemodynamic correlates to allow identification of acute responders to vasodilator treatment in idiopathic pulmonary arterial hypertension. Arch Cardiol Mex 2011;81:100-107.

119. Guía para el diagnóstico, tratamiento de la hipertensión arterial pulmonar. Documento de Consenso. Asociación Colombiana de Neumología y Cirugía de Tórax, Asociación Colombiana de Cardiología y Cirugía Cardiovascular, Asociación Colombiana de Reumatología y Asociación Colombiana de Infectología. Rev Colombiana de Neumología 2012;1-127.

120. Consenso para el diagnóstico y tratamiento de la hipertensión arterial pulmonar. Sociedad Argentina de Cardiología-SAC, Asociación Argentina de Medicina Respiratoria-AAMR y Sociedad Argentina de Reumatología-SAR. Rev Argentina de Cardiología 2011;79:1-32.

122. Londoño VA. Retos del manejo de la hipertensión arterial pulmonar en América Latina. Situación actual en Colombia. Revista Colombiana de Neumología 2008;20:109-110.

123. Denis M, Morales-Blanhir JE, Rosas Romero MJ, Martínez RC. La participación de la sociedad civil en medicina. El caso de la hipertensión pulmonar en Latinoamérica. Arch Cardiol Mex 2011;81:68-69.

124. Morales-Blanhir JE, Rosas RMJ, Robledo PJ, Londoño VA, Olivares D, Denis M. Estado actual de la hipertensión pulmonar en 3 países de Latinoamérica y la Sociedad Latina de Hipertensión Pulmonar. Rev Colombiana de Neumología 2011;23:15-20.